Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion?

PubWeight™: 1.09‹?› | Rank: Top 10%

🔗 View Article (PMID 12900277)

Published in Curr Opin Immunol on August 01, 2003

Authors

Young S Hahn1

Author Affiliations

1: Department of Microbiology and Beirne B. Carter Center for Immunology Research, University of Virginia, Health Sciences Center, Charlottesville 22908, USA. ysh5e@virginia.edu

Articles citing this

Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol (2005) 1.62

Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38

Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology (2012) 1.36

Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus. Proc Natl Acad Sci U S A (2007) 1.28

Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8+-T-cell responses. J Virol (2005) 1.28

Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. J Immunol (2008) 1.27

Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. J Biol Chem (2011) 1.22

Immune defence, parasite evasion strategies and their relevance for 'macroscopic phenomena' such as virulence. Philos Trans R Soc Lond B Biol Sci (2009) 1.20

Fas and TNFR1, but not cytolytic granule-dependent mechanisms, mediate clearance of murine liver adenoviral infection. Hepatology (2005) 1.02

Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood (2007) 0.98

Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. World J Gastroenterol (2014) 0.94

Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol (2009) 0.91

T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol (2013) 0.84

Bacterial toxins and the immune system: show me the in vivo targets. J Exp Med (2005) 0.83

Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes. Hepat Mon (2012) 0.82

Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-γ Production by Altering Cellular Metabolism via Arginase-1. J Immunol (2016) 0.80

An unbalanced PD-L1/CD86 ratio in CD14(++)CD16(+) monocytes is correlated with HCV viremia during chronic HCV infection. Cell Mol Immunol (2014) 0.77

A novel T cell evasion mechanism in persistent RNA virus infection. Trans Am Clin Climatol Assoc (2014) 0.77

Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. Clin Exp Immunol (2004) 0.76

Pathogenic potential of borna disease virus lacking the immunodominant CD8 T-cell epitope. J Virol (2007) 0.75

Hepatitis C virus infection--pathobiology and implications for new therapeutic options. Dig Dis Sci (2007) 0.75